Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04219826 · ClinicalTrials.gov registry record · Phase 2
Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
A Phase 2 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT04219826 is a Phase 2 study that has completed, run by Cytokinetics. The registered enrollment target is 96 participants.
The verdict
NCT04219826, a Phase 2 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
This study is being performed to understand the effect of different doses of CK-3773274 on patients with hypertrophic cardiomyopathy (HCM).
Interventions
- DRUG CK-3773274 (5 - 15 mg)
- DRUG CK-3773274 (10 - 30 mg)
- DRUG Placebo for CK-3773274
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2020-01-10 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04219826
The ClinicalTrials.gov registry entry for NCT04219826 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CK-3773274 (5 - 15 mg) is the first listed.
NCT04219826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04219826 about?
NCT04219826 is a clinical study titled "Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy". This study is being performed to understand the effect of different doses of CK-3773274 on patients with hypertrophic cardiomyopathy (HCM).
What is the current status of trial NCT04219826?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2020-01-10. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT04219826?
The interventions under investigation include: CK-3773274 (5 - 15 mg) (DRUG), CK-3773274 (10 - 30 mg) (DRUG), Placebo for CK-3773274 (DRUG).
Who is sponsoring clinical trial NCT04219826?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.